Article

Medicare, imaging cuts squeeze urologists, patients

Urologists and other physicians are facing another battle over Medicare fees, with a 9.9% cut looming for 2008 and further reductions that will be imposed on physicians who provide in-office imaging services as a result of the Deficit Reduction Act of 2005.

Related Videos
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Landon Trost, MD, answers a question during a Zoom video interview
Anna Myers, CNP, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
1 expert in this video
Perry Xu, MD, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Related Content
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL
"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC
March 25th 2025

Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC

Hannah Clarke
"Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC
March 24th 2025

Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC

Hannah Clarke
“The addition of the durvalumab did not make treatment more morbid than chemotherapy alone, and it didn't change or increase the surgical complications you saw in the ward," says James W.F. Catto, MBChB, PhD, FRCS.
Data reinforce isodose MHFRT as standard of care radiotherapy regimen
March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke
“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
© 2025 MJH Life Sciences

All rights reserved.